Champions Oncology, Inc.

Day range

—

Open

—

Prev close

$4.84

Volume

0

Market cap

$67.37M

Shares out

13.92M

P/E

—

P/S

1.11

P/B

17.30

P/FCF

—

ROE

-28.4%

ROA

-3.3%

Debt/Equity

0.00

Div yield

0.00%

As of Nov 9, 2026

• Annual meeting resultsOct 16, 2026

  The proposal to approve the 2026 Equity Incentive plan, as described in the Company's 2026 proxy statement, was approved by the following votes.

• Quarterly earningsSep 10, 2026

  On September 10, 2026, Champions Oncology, Inc. (the "Company") issued a press release regarding the Company's unaudited financial results for its first quarter ended July 31, 2026.

• Director appointmentMar 30, 2026

  On March 24, 2026, the Board of Directors (the "Board") of Champions Oncology, Inc. (the "Company") appointed Dr. Brian Alexander as a director of the Company to fill the vacancy created by Dr. Breitfeld's resignation. Dr. Alexander, MD, MPH, serves as the Chief Executive Officer of Valo Health Inc., a company dedicated to utilizing artificial intelligence (AI) and advanced analytics to learn from patient experiences and accelerate the discovery and development of superior medicines at increased speed and scale, since November 2024.

• Annual meeting resultsOct 16, 2025

  On October 16, 2025, Champions Oncology, Inc. (the "Company") held its Annual Meeting of Stockholders (the "Annual Meeting"). The following matters were submitted to a vote of the stockholders at the Annual Meeting and the voting results were as follows: 1. Election of Directors. The seven director nominees named in the Company's 2025 proxy statement were elected to serve for a one-year term expiring at the 2026 Annual Meeting of Stockholders or until their successors are duly elected and qualified, based upon the following votes: [detailed voting results provided]

• Executive compensation changeJul 21, 2025

  Pursuant to the agreement, he will receive an annual base salary of $500,000 and will have the opportunity to earn a discretionary target incentive bonus of 75% of his base salary. He will also receive multiple equity awards, including 225,000 options to purchase the Company's common stock, which will vest over a four-year period, and 475,000 options to purchase the Company's common stock which will vest at varying time points and are based on varying performance criteria.

Days to cover

9.4

Short interest

77.65K

Avg volume

8.27K

As of Oct 15, 2026 · reported to FINRA twice monthly.

• Champions Oncology vs. Biodesix: Which Oncology Stock Is a Better Buy?
  positiveZacks Investment Research· Nov 6, 2026
• CSBR Stock Slips Post Q1 Earnings Despite Revenue, Margin Growth
  neutralZacks Investment Research· Sep 15, 2026
• Champions Oncology (CSBR) Earnings Transcript
  neutralThe Motley Fool· Mar 13, 2026
• Insiders Buying Solid Biosciences And 2 Other Stocks
  Benzinga· Jan 16, 2024
• Insiders Buying Tilly's And 2 Other Stocks
  Benzinga· Jan 10, 2024